Back to search results

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Abroad (travel likely)RecruitingPHASE2

Conditions

High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Recurrent Medulloblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Children's Hospital Colorado, Aurora, Colorado, United States

    Contact: Study coordinator (Holly Lindsay, MD) · holly.lindsay@childrenscolorado.org · 720-777-0461
    Contact: Principal Investigator (Holly Lindsay, MD)

  • Children's National Medical Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Eugene Hwang, MD) · ehwang@childrensnational.org · 202-476-5046
    Contact: Principal Investigator (Eugene Hwang)

  • Nicklaus Children's Hospital, Miami, Florida, United States

    Contact: Study coordinator (Ziad Khatib, MD) · ziad.khatib@nicklaushealth.org · 305-662-8360

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

    Contact: Study coordinator (Ashley Plant, MD) · aplant@luriechildrens.org · 312-227-4090
    Contact: Principal Investigator (Ashley Plant, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Karen Wright, MD) · KarenD_wright@dfci.harvard.edu · 617.632.4309
    Contact: Principal Investigator (Karen Wright, MD)

  • C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States

    Contact: Study coordinator (John Prensner, MD) · prensner@med.umich.edu · 8669094449

  • St. Louis Children's Hospital, St Louis, Missouri, United States

    Contact: Study coordinator (Eric M Thompson, MD) · pedshemonctrialreferral@wustl.edu
    Contact: Principal Investigator (Eric M Thompson, MD)

  • Duke Cancer Center, Durham, North Carolina, United States

    Contact: Study coordinator (Daniel Landi, MD) · pedsneuronc@duke.edu · 919-684-5013
    Contact: Principal Investigator (Daniel Landi, MD)

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Peter de Blank, MD) · Peter.deBlank@cchmc.org · 513-517-2068
    Contact: Principal Investigator (Peter de Blank, MD)

  • Nationwide Children's Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Melinda Triplet) · melinda.triplet@nationwidechildrens.org · 614-722-6039
    Contact: Principal Investigator (Maryam Fouladi, MD)

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Michael J Fisher, MD) · fisherm@email.chop.edu · 215-590-5188
    Contact: Principal Investigator (Michael J Fisher, MD)

  • Texas Children's Hospital, Houston, Texas, United States

    Contact: Study coordinator (Patricia Baxter, MD) · pabaxter@txch.org · 832-824-4681
    Contact: Principal Investigator (Patricia Baxter, MD)

  • Seattle Children's Hospital, Seattle, Washington, United States

    Contact: Study coordinator (Sarah Leary, MD) · sarah.leary@seattlechildrens.org · 206-987-2106
    Contact: Principal Investigator (Sarah Leary, MD)
Study leads

  • Daniel Landi, MD

    Study Chair

    Duke Cancer Center

  • Eric M Thompson, MD

    Study Chair

    Washington University - St. Louis Children's Hospital

  • Maryam Fouladi, MD

    Principal Investigator

    Nationwide Children's Hospital

View source on ClinicalTrials.gov(opens in a new tab)